To remedy this problem, TSCL supports Social Security "caregiving credits." These credits would be applied to a worker's Social Security earnings record to make up for years when people took time out of their working careers, and earned little or zero income, because they were caring for children, spouses, or older family members. .TSCL is deeply concerned about the prospect of cuts to benefits and COLAs. Seniors can ill afford any reduction in benefits once they have already retired and are depending on them for their daily expenses. We urge you to learn how Congressional candidates stand on changes to Social Security and Medicare. To learn whether your U.S. Representative or Senators support legislation of interest to you, visit the TSCL website at or call toll free 1-800-333-8725. .The chances for legislation remain strong as more experts say older seniors need a benefit boost to protect them from outliving their retirement resources. Your continued support, letters, and phone calls to Members of Congress make all the difference in building co-sponsorship. TSCL has been instrumental in building support for the Notch Fairness legislation and remains committed to passage. .To learn more and participate in surveys visit . .It would have to report to Congress every two years on regulatory and financial developments that affect older investors. Reports would have to include recommendations for possible regulatory or legislative action. .d freedoms as U.S. Citizens, and to protect and defend the benefits senior citizens have earned and paid for. The Senior Citizens League is a proud affiliate of The Retired Enlisted Association. Visit for more information. .Sources: "Advocates Head To Court To Overturn Medicare Rules For Observation Care," Susan Jaffee, Kaiser Health News and USA Today, May 3, 2013. .After the drug executives announced they would not meet with the President, he went on Twitter and accused the pharmaceutical industry of running ads that lied about his new executive order. .Every other developed country has evolved schemes to set or negotiate prices, while balancing cost, efficacy and social good. The United States instead has let business calculations drive drug price tags, forcing us to accept and absorb ever higher costs. That feels particularly galling for treatments and vaccines against COVID-19, whose development and production is being subsidized and incentivized with billions in federal investment.